Uppsala, June 9, 2022. Meet Dicot's CEO Elin Trampe at Småbolagsdagarna on Monday June 13 when she presents the company's development of a new potency drug and the latest advances. Among other things, she will talk about a newly started project with Uppsala University and raise the issue of the culture of silence among men with erectile dysfunction.
Location: Hotel Birger Jarl, Tulegatan 8 in Stockholm
Time: Monday June 13:th, at 10:30-11:00
Registration: https://www.lyyti.fi/reg/Smabolagsdagarna_2022_1220
Live broadcast: www.aktiespararna.se/tv/live
It is possible to ask your own questions to Elin Trampe which will be answered during the interview following the presentation. Send them by SMS to 079-347 98 45 or email to event@aktiespararna.se and they will be forwarded to the moderator. The questions can be sent in from now until Elin Trampe ends the presentation.
For further information, please contact:
Elin Trampe, CEO
Tel: +46 739 80 14 08
Email: elin.trampe@dicot.se
About Dicot AB
Dicot is developing the drug candidate LIB-01, which will be a potency agent to better treat erectile dysfunction and premature ejaculation. The ambition is to create a drug with significantly longer effect and far fewer side effects, compared to those on the market. Research and development are conducted under own auspices up to phase 2 studies. Thereafter, Dicot's intention is to form strategic alliances, or alternatively carry out a trade sale, with larger, established pharmaceutical companies to be able to introduce LIB-01 on the world market.
Dicot is listed on Spotlight Stock Market and has approximately 3,300 shareholders. For more information, please visit www.dicot.se.